HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 633 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas September 9, 2020 Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker November 23, 2021 Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... December 6, 2023 Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma December 9, 2020 Load more HOT NEWS Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer Diagnosed Alone Working to Raise Prostate Cancer Awareness: A Patient Advocate’s Story ESMO Targeted Anticancer Therapies Congress 2021, 1-2 March
